Overall rank by patents
#35,149
Across all tracked assignees
USPTO PatentsView assignee record - 7 granted patents across 6 technology areas, active 2022–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12P (FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE).
The verdict
Enzymaster holds 7 US patents across 6 technology areas, rank #35,149 of 50,000 tracked assignees.
Enzymaster (ningbo) Bio-engineering Co., Ltd. has been granted 7 US utility patents between 2022 and 2024, placing Enzymaster (ningbo) Bio-engineering Co., Ltd. at rank #35,149 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.7 claims per patent with primary concentration in C12P (FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE). As a Foreign Corporation, Enzymaster (ningbo) Bio-engineering Co., Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, Enzymaster sits between ENEA Agenzia Nazionale PER LE Nuove Tecnologie, L'energia E LO Sviluppo Economico Sostenibile (7 patents, rank #35,145) and Epileds Technologies, Inc. (7 patents, rank #35,153) - the closest US assignees by grant volume. The composite Innovation Score of 44.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2024, with 7 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Enzymaster (ningbo) Bio-engineering Co., Ltd.'s 14.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Enzymaster (ningbo) Bio-engineering Co., Ltd. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
ENEA AGENZIA NAZIONALE PER LE NUOVE TECNOLOGIE, L'ENERGIA E LO SVILUPPO ECONOMICO SOSTENIBILE
7 patents
ENERGY CONTROL LIMITED
7 patents
ENPRESS LLC
7 patents
ENYO PHARMA
7 patents
EOLAS THERAPEUTICS, INC
7 patents
EON REALITY, INC.
7 patents
EOSPACE INC.
7 patents
EPILEDS TECHNOLOGIES, INC.
7 patents
ENZYMASTER (NINGBO) BIO-ENGINEERING CO., LTD.
7 patents
What this shows Enzymaster holds 7 patents at rank #35,149, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #35,149 in granted patent volume.
Other assignees with the most granted patents in Enzymaster's primary technology class.
Enzymaster's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
45 Top 25% higher than 75% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 4 | 57.1% |
| 2024 | 3 | 42.9% |
Top 6 of 6 technology areas
Overall rank by patents
#35,149
Across all tracked assignees
44.7 out of 100
How to use this portfolio
Enzymaster's 7 grants land it in the top 25% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.